GLP-1 Titration Schedule: How Dose Increases Are Timed
Titration is the slow, step by step rise from a low starting dose to the dose a person stays on, and every GLP-1 label publishes its own version of it. This page explains what a GLP-1 titration schedule is, why the steps are spaced at least 4 weeks apart, and why prescribers often slow or pause the climb. It is education only, not personal dosing advice.
What titration means
Titration is the process of starting a medicine at a low dose and raising it in planned steps until the dose that works best for that person is reached. The low start is not the treatment dose. It is a settling in period that lets the body adjust to effects that would be much harder to tolerate if the full dose arrived on day one. With GLP-1 medicines those effects are mainly digestive, because the medicines slow stomach emptying and reduce appetite, and both actions are dose related. The stronger the dose, the stronger those actions tend to feel, especially in the first days after a change.
A GLP-1 titration schedule is therefore built into the FDA approved labels themselves. Each brand label publishes its starting dose, its step sizes and the minimum time to spend at each step. Prescribers work inside that published frame. They do not invent a personal ladder, although they can and do move through the published ladder more slowly than the fastest version when a person's response calls for it.
The published patterns, in brief
Both medicine families use the same basic rhythm, a starting dose for 4 weeks, then steps with at least 4 weeks between them. Semaglutide brands start at 0.25 mg once a week. Ozempic can then rise through 0.5 mg and 1 mg to a maximum of 2 mg, while Wegovy continues through 1.7 mg to a 2.4 mg maintenance dose. Tirzepatide brands, Mounjaro and Zepbound, start at 2.5 mg once a week and rise by 2.5 mg per step to a maximum of 15 mg, with 5 mg, 10 mg and 15 mg named as the Zepbound maintenance doses. The full tables are on the semaglutide dose schedule and tirzepatide dose schedule pages.
| Medicine | Starting dose | Step pattern | Top of schedule |
|---|---|---|---|
| Semaglutide (Ozempic) | 0.25 mg weekly | Increases only when the prescriber decides more effect is needed | 2 mg weekly maximum |
| Semaglutide (Wegovy) | 0.25 mg weekly | 0.5 mg, 1 mg, 1.7 mg, then maintenance | 2.4 mg weekly maintenance |
| Tirzepatide (Mounjaro, Zepbound) | 2.5 mg weekly | Plus 2.5 mg per step, at least 4 weeks apart | 15 mg weekly maximum |
Why steps are spaced at least 4 weeks apart
The first reason is how slowly these medicines leave the body. Semaglutide has a half-life of about 1 week and tirzepatide a half-life of about 5 days, so after a dose increase the level in the system keeps building for several weeks before it settles. Judging a dose after only a week or two would mean judging it before its full effect has arrived. Four weeks gives the level time to approach its settled state and gives benefits and side effects time to show their real pattern.
The second reason is tolerability. Side effects such as nausea, vomiting and diarrhea are most common in the days around an increase and usually ease as the body adjusts. Spacing the steps out separates those adjustment periods, so each one can settle before the next begins. The third reason is fairness of judgment. Blood sugar change and weight change are both slow signals. A month at a dose produces information a prescriber can actually use, while a week produces mostly noise.
Why prescribers slow or pause escalation
A slower titration is not a failed titration. Prescribers commonly hold a dose for longer when side effects are strong or not settling, when the current dose is already doing its job well, or when life circumstances make a rough adjustment week a bad idea. They may also return someone to the last dose that was tolerated, pause treatment entirely, or stop the medicine. Pauses are also common before planned surgery, because these medicines slow stomach emptying, and people planning a pregnancy are generally advised to stop treatment ahead of time under their prescriber's direction.
What a prescriber will not do is speed the schedule up beyond the published steps to reach a target faster. The labels set the minimum spacing, and going faster would stack a new increase on top of a level that is still building, which is when side effects are most likely to become severe. If your schedule feels slow, that is the safety design working as intended, not time being wasted.
What reaching a maintenance dose means
Titration ends when a dose is reached that balances effect and tolerability for that person, and that dose is then continued. For Wegovy the label names 2.4 mg once a week as the maintenance dose, with 1.7 mg if 2.4 mg is not tolerated. For Zepbound the named maintenance doses are 5 mg, 10 mg or 15 mg once a week. For the diabetes brands, Ozempic and Mounjaro, the working dose is whichever published dose the prescriber settles on, up to the 2 mg and 15 mg maximums. Staying on a lower dose because it works and feels manageable is a normal outcome of titration, not a lesser one.
Keeping a record while you titrate
A brief note of each dose, its start date and how the following weeks felt gives your prescriber exactly the evidence titration decisions are based on. Note digestive side effects, how long they lasted after each increase, and anything that made them easier or worse. Patterns that are obvious in a written record can be hard to reconstruct from memory at an appointment months later, and a clear record is often the difference between a confident decision to increase, hold or step back, and a guess.
Frequently asked questions
What does titration mean for GLP-1 medicines?
Titration means starting at a low dose and increasing in planned steps, with time at each step, until the dose that balances effect and tolerability is reached. The starting doses on GLP-1 labels, 0.25 mg for semaglutide and 2.5 mg for tirzepatide, are initiation doses meant to let the body adjust, not full treatment doses.
Why are GLP-1 dose increases at least 4 weeks apart?
Because these medicines leave the body slowly, semaglutide with a half-life of about 1 week and tirzepatide with a half-life of about 5 days, the level in the system builds for weeks after an increase. Four weeks lets the level settle, lets side effects ease, and gives the prescriber a fair reading of what the dose is doing before the next step.
Can a titration schedule be slower than the chart?
Yes, and it commonly is. The charts show the minimum time at each dose, not a required speed. Prescribers often hold a dose for longer because of side effects or because the current dose is already working well, and that slower path is still the published schedule being followed as intended.
What happens if side effects appear after an increase?
Tell your prescriber. Common responses include staying on the current dose for longer, returning to the previous dose that was tolerated, pausing treatment, or stopping the medicine. Side effects such as nausea, vomiting and diarrhea are most common around increases, which is why prescribers manage the pace rather than pushing through a set calendar.
Is the starting dose meant to produce results?
Not mainly. The starting dose exists so the body can get used to the medicine. The semaglutide labels and the Mounjaro label treat their starting doses as initiation steps, and the treatment effect is expected to build as the dose rises through the published steps toward a maintenance dose.